Gilead Sciences (GILD) Tops Q2 EPS by 6c, Offers Guidance

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/7/2026

1. MRVL
2. ZS
3. PENG
4. NVDA
5. STZ
6. MSFT
7. SPY
8. SKYD
9. IBM
10. CRWV

Go back to Gilead Sciences (GILD) Tops Q2 EPS by 6c, Offers Guidance

Gilead Sciences Announces Second Quarter 2022 Financial Results

August 2, 2022 4:01 PM EDT

Biktarvy Sales Increased 28% Year-Over-Year to $2.6 billion

Oncology Sales Increased 71% Year-Over-Year to $527 million

FOSTER CITY, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the second quarter of 2022.

This was a very strong quarter for Gilead, with solid commercial and clinical execution, said Daniel ODay, Chairman and Chief Executive Officer, Gilead Sciences. Excluding Veklury, product sales grew 7% year-over-year. There was continued strong demand for our HIV portfolio with further share growth for Biktarvy, and oncology revenues reached an all-time... More